Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding

Area of Science:

• Gynecology
• Reproductive Health
• Pharmacology

Background:

• Dysfunctional uterine bleeding (DUB) encompasses various abnormal uterine bleeding patterns.
• Metrorrhagia, menometrorrhagia, oligomenorrhea, and polymenorrhea are common DUB types.
• Effective management of DUB is crucial for improving women's quality of life.

Purpose of the Study:

• To evaluate the efficacy of a triphasic oral contraceptive (OC) containing norgestimate and ethinyl estradiol (E2).
• To compare this OC's effectiveness against a placebo in treating specific DUB types.
• To assess the impact on bleeding patterns and quality of life.

Main Methods:

• A multicenter, randomized, double-masked study involving 201 women aged 15-50 with DUB.
• Participants received either triphasic norgestimate-ethinyl E2 or a placebo for three 28-day cycles.
• Efficacy was measured by investigator/subject assessments of DUB resolution, bleeding patterns, and quality of life changes.

Main Results:

• Over 80% of subjects on the triphasic OC showed improved bleeding patterns versus fewer than 50% on placebo (P <.001).
• Significantly fewer subjects on the triphasic OC reported abnormal bleeding patterns (P <.001).
• Improvements in physical functioning were significantly greater in the triphasic OC group.

Conclusions:

• The triphasic combination of norgestimate and ethinyl E2 is an effective treatment for DUB.
• This OC demonstrates significant benefits in managing metrorrhagic, menometrorrhagic, oligomenorrheic, and polymenorrheic bleeding.
• The treatment positively impacts physical functioning, suggesting improved quality of life.